{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:14:15Z","timestamp":1790748855607,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). This analysis of 168 patients (mean age, 54.8 years) from a multicenter, retrospective chart review describes the clinical course, treatment patterns, hospitalizations, and clinical outcomes of patients aged \u226512 years who developed grades II\u2013IV acute GVHD after their first allogeneic HCT (January 1, 2014, to June 30, 2016) and were refractory to or dependent on corticosteroids. Between diagnosis and maximum grade (median, 6.0 days), 53.6% of patients had new organ involvement, particularly lower gastrointestinal tract acute GVHD, or an increase in acute GVHD grade. Eighty-nine patients (53.0%) received additional systemic GVHD therapy (after systemic corticosteroids) within a median of 21.0 days. Hospital readmission(s) was required for 56.5% of patients within 100 days post-HCT (mean inpatient length of readmission stay, 49.5 days); 24.4% had \u22652 readmissions within 100 days post-HCT. From the date of acute GVHD diagnosis, 70.2% of patients died at a median (interquartile range) of 117.5 (49\u2013258) days. In summary, steroid-refractory and steroid-dependent acute GVHD is associated with a rapidly worsening clinical course that leads to high readmission and mortality rates, emphasizing the need for effective and tolerable therapies.<\/jats:p>","DOI":"10.1038\/s41409-022-01736-0","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T14:03:37Z","timestamp":1655993017000},"page":"1399-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study"],"prefix":"10.1038","volume":"57","author":[{"given":"Shernan G.","family":"Holtan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joachim Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"1736_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443\u201358.","journal-title":"Nat Rev Immunol"},{"key":"1736_CR2","unstructured":"D\u2019Souza A, Fretham C Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2019. Available at: https:\/\/www.cibmtr.org. Accessed April 14, 2020."},{"key":"1736_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296\u2013307.","journal-title":"Blood"},{"key":"1736_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/TP.0000000000002932","volume":"104","author":"MM Al Malki","year":"2020","unstructured":"Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus\/sirolimus-based GVHD prophylaxis: Impact of HLA mismatch. Transplantation. 2020;104:1070\u201380.","journal-title":"Transplantation"},{"key":"1736_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.bbmt.2019.11.016","volume":"26","author":"K Ballen","year":"2020","unstructured":"Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, et al. Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: a study of 2456 umbilical cord blood recipients. Biol Blood Marrow Transpl. 2020;26:745\u201357.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR6","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3389\/fimmu.2019.02319","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Lorentino F, Nitti R, Lupo Stanghellini MT, Giglio F, Clerici D, et al. Interleukin-6 as biomarker for acute GvHD and survival after allogeneic transplant with post-transplant cyclophosphamide. Front Immunol. 2019;10:2319.","journal-title":"Front Immunol"},{"key":"1736_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/2040620713489842","volume":"4","author":"C Garnett","year":"2013","unstructured":"Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv. Hematol. 2013;4:366\u201378.","journal-title":"Ther Adv. Hematol"},{"key":"1736_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","volume":"54","author":"L Axt","year":"2019","unstructured":"Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2019;54:1805\u201314.","journal-title":"Bone Marrow Transpl"},{"key":"1736_CR9","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","volume":"131","author":"H Major-Monfried","year":"2018","unstructured":"Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846\u201355.","journal-title":"Blood"},{"key":"1736_CR10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.bbmt.2017.03.010","volume":"23","author":"MN Stauber","year":"2017","unstructured":"Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, et al. Early hyperglycemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease. Biol Blood Marrow Transpl. 2017;23:1186\u201392.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"1736_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/asheducation.V2012.1.251.3798879","volume":"2012","author":"SZ Pavletic","year":"2012","unstructured":"Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Hematol Am Soc Hematol Educ Program. 2012;2012:251\u201364.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1736_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","volume":"158","author":"FL Dignan","year":"2012","unstructured":"Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30\u201345.","journal-title":"Br J Haematol"},{"key":"1736_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbmt.2019.10.028","volume":"26","author":"J Yu","year":"2020","unstructured":"Yu J, Judy JT, Parasuraman S, Sinha M, Weisdorf D. Inpatient healthcare resource utilization, costs, and mortality in adult patients with acute graft-versus-host disease, including steroid-refractory or high-risk disease, following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:600\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41409-018-0215-4","volume":"53","author":"CKK Ma","year":"2018","unstructured":"Ma CKK, Garcia-Cadenas I, Fox ML, Ai S, Nivison-Smith I, Milliken ST, et al. Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. Bone Marrow Transpl. 2018;53:1478\u201382.","journal-title":"Bone Marrow Transpl"},{"key":"1736_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52:859\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"1736_CR17","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/j.bbmt.2019.12.742","volume":"26","author":"J Yu","year":"2020","unstructured":"Yu J, Holtan S, Hanna B, Paranagama D, Tang J, Choe H, et al. Disease progression, treatment patterns, hospitalization, and clinical outcomes of patients with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (HSCT): A multicenter chart review. Biol Blood Marrow Transpl. 2020;26:S181.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","volume":"18","author":"A Xhaard","year":"2012","unstructured":"Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A, et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transpl. 2012;18:406\u201313.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/stem.2224","volume":"34","author":"F von Dalowski","year":"2016","unstructured":"von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: Clinical responses and long-term outcome. Stem Cells. 2016;34:357\u201366.","journal-title":"Stem Cells"},{"key":"1736_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","unstructured":"Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transpl. 2016;22:1102\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1736_CR21","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 2020;7:e157\u2013e167.","journal-title":"Lancet Haematol"},{"key":"1736_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-020-0804-2","volume":"34","author":"F Malard","year":"2020","unstructured":"Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34:1229\u201340.","journal-title":"Leukemia"},{"key":"1736_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA approval summary: Ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25:e328\u2013e334.","journal-title":"Oncologist"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01736-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:05:41Z","timestamp":1662131141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01736-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1736"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01736-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SGH has served as a consultant for Bristol-Myers Squibb, CSL Behring, Generon Corporation, and Incyte Corporation. JT is an employee of Asclepius Analytics, which received funding for this project from Incyte Corporation. JY, DP, AN, and JG are employees and shareholders of Incyte Corporation. HKC has nothing to disclose. HJD previously received consulting fees from Incyte Corporation. JG previously received consulting fees from and is currently an employee and shareholder of Incyte Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}